Cercar

01/07/2025 Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial
Ryan, P, Blanco, JL, Masia, M, Garcia-Fraile, L, Crusells, MJ, Domingo, P, Curran, A, Guerri-Fernandez, R, Bernal, E, Bravo, J, Revollo, B, Macias, J, Tiraboschi, JM, Montejano, R, Amador, C, Torralba, M, Merino, D, Diaz-Brito, V, Galindo, MJ, Ferra, S, Villoslada, A, Losa, JE, Fanjul, FJ, Perez-Stachowski, X, Peraire, J, Portilla, J, de la Fuente, S, Dueñas, C, Vazquez, MJ, Di Gregorio, S, Esteban, H, Gil, P, de Miguel, M, Alejos, B, Martínez, E. Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial. Lancet HIV. 2025; 12(7)DOI:10.1016/S2352-3018(25)00105-5. PMID:40489982. IF:13.000(Q1/1D).
01/04/2025 Antiviral effect, safety, and tolerability of the third-generation integrase strand transfer inhibitor VH4524184 (VH-184): a proof-of-concept trial
Rogg, L, Nuñez, SA, Mingrone, MVO, Domingo, P, Lopez, M, Hanan, N, Ghita, GL, Jeffrey, JL, Underwood, M, Castillo-Mancilla, JR, Halliday, F, Ezeadi, E, Gartland, M. Antiviral effect, safety, and tolerability of the third-generation integrase strand transfer inhibitor VH4524184 (VH-184): a proof-of-concept trial. HIV MEDICINE. 2025; 26DOI:. PMID:. IF:3.200(Q2/4D).
04/03/2025 Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial
Bailón, L, Moltó, J, Curran, A, Cadiñanos, J, de Quirós, JCLB, de los Santos, I, Ambrosioni, J, Imaz, A, Benet, S, Suanzes, P, Navarro, J, González-García, J, Busca, C, Pérez-Latorre, L, Berenguer, J, García-Fraile, LJ, Mejia-Abril, G, Miró, JM, Scévola, S, Moreno, S, Domingo, P, Tian, Y, Frankot, M, Lim, D, Cai, YH, Vendrame, E, Guo, S, Wallin, JJ, Geleziunas, R, Sengupta, D, Alarcón-Soto, Y, Leal, I, Aranguen, A, Garcia-Garcia, M, McGowan, I, Brander, C, Arribas, JR, Mothe, B. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-57284-w. PMID:40038256. IF:15.700(Q1/1D).
01/02/2025 Blood CD45+/CD3+ lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019
Suades, R, Greco, MF, Padró, T, de Santisteban, V, Domingo, P, Benincasa, G, Napoli, C, Greco, S, Madè, A, Ranucci, M, Devaux, Y, Martelli, F, Badimon, L. Blood CD45+/CD3+ lymphocyte-released extracellular vesicles and mortality in hospitalized patients with coronavirus disease 2019. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2025; 55(2)DOI:10.1111/eci.14354. PMID:39548690. IF:3.600(Q1/2D).